Version 1
: Received: 25 January 2024 / Approved: 25 January 2024 / Online: 25 January 2024 (15:51:41 CET)
How to cite:
Ansah, E.O.; Nyarko, B.A. Current Advances in Bispecific T Cell–Engaging Therapies. Preprints2024, 2024011861. https://doi.org/10.20944/preprints202401.1861.v1
Ansah, E.O.; Nyarko, B.A. Current Advances in Bispecific T Cell–Engaging Therapies. Preprints 2024, 2024011861. https://doi.org/10.20944/preprints202401.1861.v1
Ansah, E.O.; Nyarko, B.A. Current Advances in Bispecific T Cell–Engaging Therapies. Preprints2024, 2024011861. https://doi.org/10.20944/preprints202401.1861.v1
APA Style
Ansah, E.O., & Nyarko, B.A. (2024). Current Advances in Bispecific T Cell–Engaging Therapies. Preprints. https://doi.org/10.20944/preprints202401.1861.v1
Chicago/Turabian Style
Ansah, E.O. and Bernard Ansong Nyarko. 2024 "Current Advances in Bispecific T Cell–Engaging Therapies" Preprints. https://doi.org/10.20944/preprints202401.1861.v1
Abstract
The emergence of bispecific antibodies has transformed cancer immunotherapy, highlighting increased clinical efficacy, especially in hematological malignancies. These innovative molecules uniquely target two distinct tumor antigens or separate epitopes simultaneously, demonstrating potent antitumor activity across various cancers. Despite their promise, challenges like rapid drug clearance, off-target effects, and cytokine release syndrome hinder their widespread therapeutic application. Recent engineering advancements in bispecific antibody systems aim to overcome these challenges, broadening therapeutic coverage. This review offers insights into the latest clinical and preclinical progress in bispecific immunotherapy, outlining key challenges faced by the technique, and exploring emerging strategies to address these obstacles.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
